Research Centers
- Cancer Biology
- Cardiovascular Health
-
Children's Health
- The Sanford Project
- Available Faculty Positions
Primary Faculty
- Baack Lab
- Guo Lab
- H. Eugene Hoyme
- Kinkel Lab
- Kruer Lab
- Lee Lab
- Pearce Lab
- Alex Rabinovitch
- Roux Lab
- Savinov Lab
- Surendran Lab
- Vitiello Lab
- Weimer Lab
- Zhao Lab
Secondary Faculty
- Amy Elliott
- Dennis Stevens
- Michael Bergeron
- Patricia Crotwell
Adjunct Faculty
- Seasson Vitello
- Health Outcomes & Prevention
- NIAHP
- Homepage >
- Research Centers >
- Cancer Biology >
- Subhash Chauhan Lab >
- Press Releases
Press Releases
Curcumin nanoparticles the key to resistant cancers Pre-treatment with curcumin, a component of the spice turmeric, makes ovarian cancer cells more vulnerable to chemo- and radio-therapy. Researchers writing in BioMed Central’s open access Journal of Ovarian Research found that delivering the curcumin via very small (less than 100nm) nanoparticles enhanced the sensitizing effect. Subhash Chauhan, PhD and Meena Jaggi, PhD led a team of researchers from the Sanford Research/USD and University of South Dakota, USA, carried out the in vitro study. They said, “One strategy to improve the effectiveness and limit the toxicity of cancer therapy is to induce chemo/radio-sensitization in cancer cells using natural dietary phytochemicals like curcumin. However, curcumin is poorly absorbed by the body, which limits its effectiveness; therefore, we have developed a nanoparticle formulation, Nano-CUR, to provide increased bioavailability as well as targeted delivery of curcumin into tumors”. The researchers tested the effects of their curcumin formulation on therapy-resistant ovarian cancer cells. They were able to show, for the first time, that the pre-treatment lowers the dose of cisplatin and radiation treatment needed to suppress the growth of the cancer cells. According to Chauhan, “Nanoparticle mediated curcumin delivery will further improve the sensitization and therapeutic capabilities. This study demonstrates a novel pre-treatment strategy that could be implemented in pre-clinical animal models and in future clinical trials”. |